Beta Drugs Q2 results, quarter to Sep 2026
NSE: BETAPharmaceuticals & BiotechnologySmall Cap
Beta Drugs Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 2017 · Issue price ₹85
Last close ₹1,934.20down ₹43.70 (2.21%)
Share price at the NSE close on 27 Oct 2026. Previous close ₹1,977.90.
27 Oct: open ₹1,977.90, high ₹2,028.00, low ₹1,862.10
52-week range of traded prices to 27 Oct 2026
₹990.10Low, 25 Feb 2026₹2,807.90High, 12 Aug 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 27 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,151 Cr1,305th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.91
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 16.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 60,45338.6% delivered
Beta Drugs filed its Q2 results for the quarter to Sep 2026 on 22 Oct 2026 at 5:29 pm, standalone: the listed company alone, without its subsidiaries.
Q2 results, quarter to Sep 2026
- RevenueRevenue from operations. Money earned from selling the company's goods and services in the period. Revenue from operations in the glossary
- ₹58 Cr+3.9% on the quarter beforeChange on a year ago and on the quarter before. The change against the same quarter a year before: (this quarter's figure less that quarter's) divided by that quarter's, times 100. The change on the quarter before is the same sum against the quarter just before, taken as this quarter's results restate it where the company restated it: this quarter's year to date less this quarter. Left out where either figure is a loss, where the restatement covers two or more earlier quarters without saying which, or across a change of basis named under the table, on the lines it affects.
- Operating profitOperating profit before depreciation (EBITDA). Revenue less operating expenses: what the business earns from its operations before depreciation, interest and tax. Operating profit before depreciation (EBITDA) in the glossary
- ₹6.39 Cr−37.1% on the quarter before
- Net profitNet profit. What is left of revenue and other income after every cost, interest and tax. Net profit in the glossary
- ₹3.71 Cr−37.4% on the quarter before
- Earnings per shareEarnings per share. Profit belonging to shareholders divided by the number of shares, restated for later splits and bonuses so they do not break the line. Earnings per share in the glossary
- ₹3.29−40.7% on the quarter beforeChange on a year ago and on the quarter before. The change against the same quarter a year before: (this quarter's figure less that quarter's) divided by that quarter's, times 100. The change on the quarter before is the same sum against the quarter just before, taken as this quarter's results restate it where the company restated it: this quarter's year to date less this quarter. Left out where either figure is a loss, on the quarter before wherever the profit of that quarter was restated, and across a change of basis named under the table, on the lines it affects.
- Operating marginOperating margin. Operating profit before depreciation as a percentage of revenue: how much of each rupee of sales is left after running costs. Operating margin in the glossary
- 11.0%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 6.4%
From revenue to net profit, ₹ crore
- Revenue58
- Materials and goods−29
- Employee costs−9.4
- Other expenses−13
- Operating profit6.4
- Depreciation−2.6
- Other income+1.9
- Finance costs−0.7
- Profit before tax5.0
- Tax−1.3
- Net profit3.7
Beta Drugs results by quarter
Standalone: the listed company alone, without its subsidiaries. Latest quarter to Sep 2026. Results for the quarter to Dec 2026 are due by 14 Feb 2027, 45 days after it ends. Every company's dates are on the results calendar.Results filings and date
Revenue and net profit by quarter, ₹ crore
- Revenue
- Net profit
Peak revenue ₹58 Cr, quarter to Sep 2026; lowest ₹50 Cr, quarter to Dec 2025
Operating and net margin by quarter, per cent
- Operating margin
- Net margin
| ₹ crore | Dec 2025Q3Filed 14 Feb | Mar 2026Q4Filed 14 May | Jun 2026Q1Filed 20 Jul | Sep 2026Q2Filed 22 Oct |
|---|---|---|---|---|
| Revenue from operations | 50.3 | 54.3 | 55.8 | 58.0 |
| Operating expenses. What the business spent to run itself in the period, materials, staff and other costs, before depreciation, interest and tax. Operating expenses in the glossary | 43.7 | 44.6 | 45.7 | 51.6 |
| Materials and goods boughtCost of materials and goods. Raw materials used and goods bought for resale in the period, adjusted for the change in stock held. Cost of materials and goods in the glossary | 26.1 | 22.5 | 25.8 | 29.3 |
| Employee costsEmployee costs. Salaries, wages, bonuses and other benefits paid to staff in the period. Employee costs in the glossary | 8.2 | 9.2 | 9.4 | 9.4 |
| Other expensesOther expenses. Every operating cost besides materials and staff: power, rent, freight, repairs, marketing and the like. Other expenses in the glossary | 9.3 | 12.8 | 10.5 | 12.9 |
| Operating profit before depreciation | 6.5 | 9.8 | 10.2 | 6.4 |
| Operating margin | 13.0% | 18.0% | 18.2% | 11.0% |
| Depreciation and amortisationDepreciation and amortisation. The part of the cost of plant, buildings and other long-lived assets charged against each year they are used. Depreciation and amortisation in the glossary | 2.5 | 2.7 | 2.5 | 2.6 |
| Other incomeOther income. Income from outside the main business, such as interest on deposits, dividends received and gains on investments. Other income in the glossary | 2.5 | 2.9 | 1.9 | 1.9 |
| Finance costsFinance costs. Interest and the other costs of borrowing in the period. Finance costs in the glossary | 3.2 | 2.9 | 1.6 | 0.7 |
| One-off itemsExceptional items. Gains or losses the company reports separately because they are not expected to recur, such as selling a business or writing down an asset. Exceptional items in the glossary | 0.0 | 0.0 | 0.0 | 0.0 |
| Profit before tax | 3.4 | 7.1 | 7.9 | 5.0 |
| 0.1 | 1.7 | 2.0 | 1.3 | |
| Tax rateEffective tax rate. Tax charged as a percentage of profit before tax. Effective tax rate in the glossary | 3.6% | 24.4% | 25.2% | 25.4% |
| Net profit | 3.3 | 5.3 | 5.9 | 3.7 |
| Other comprehensive incomeOther comprehensive income. Gains and losses booked straight to net worth rather than through profit, such as changes in the value of some investments, pension plans and currency translation. Other comprehensive income in the glossary | 0.0 | 0.2 | 0.0 | 0.0 |
| Total comprehensive incomeTotal comprehensive income. Net profit plus other comprehensive income. Total comprehensive income in the glossary | 3.3 | 5.5 | 5.9 | 3.7 |
| Net margin | 6.5% | 9.8% | 10.6% | 6.4% |
| Earnings per share | ₹3.21 | ₹5.26 | ₹5.55 | ₹3.29 |
Earnings per share in rupees, restated for later splits and bonuses.
Beta Drugs results by half year
Standalone: the listed company alone, without its subsidiaries. The half years to Sep 2025 in the same span that the quarters on record do not fully cover.
| ₹ crore | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025Filed 15 May | Sep 2025Filed 6 Nov |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 65 | 78 | 80 | 92 | 105 | 118 | 102 | 121 |
| 53 | 62 | 64 | 73 | 91 | 98 | – | 109 | |
| Materials and goods bought | 37 | 41 | 42 | 50 | 62 | 64 | 56 | 74 |
| Employee costs | 5 | 7 | 7 | 7 | 8 | 9 | – | 10 |
| Other expenses | 10 | 14 | 16 | 16 | 21 | 25 | – | 25 |
| Operating profit before depreciation | 13 | 16 | 15 | 19 | 14 | 20 | – | 12 |
| Operating margin | 19.3% | 20.2% | 19.3% | 20.7% | 13.7% | 17.3% | – | 10.1% |
| Depreciation and amortisation | 3 | 3 | 3 | 3 | 2 | 3 | – | 4 |
| Other income | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 6 |
| Finance costs | 0 | 0 | 1 | 1 | 0 | 1 | 4 | 6 |
| Profit before one-off items and taxProfit before one-off items and tax. Profit before tax as it would be without the one-off items below it, as the company states it. Profit before one-off items and tax in the glossary | 10 | 13 | 12 | 16 | 13 | 18 | 8 | 8 |
| One-off items | 0 | 0 | 0 | 0 | 0 | 0 | – | – |
| Profit before tax | 10 | 13 | 12 | 16 | 13 | 18 | 3 | 8 |
| 3 | 3 | 3 | 4 | 3 | 5 | 1 | 2 | |
| Tax rate | 29.5% | 25.2% | 25.6% | 25.3% | 26.0% | 25.5% | 28.8% | 26.1% |
| Net profit | 7 | 10 | 9 | 12 | 10 | 13 | 2 | 6 |
| Net margin | 10.6% | 12.4% | 11.4% | 13.1% | 9.3% | 11.2% | 2.1% | 4.8% |
| Earnings per share | – | – | – | – | – | – | ₹2.12 | – |
Earnings per share in rupees, restated for later splits and bonuses.